STOCK TITAN

Meiragtx Holdings Plc - MGTX STOCK NEWS

Welcome to our dedicated page for Meiragtx Holdings Plc news (Ticker: MGTX), a resource for investors and traders seeking the latest updates and insights on Meiragtx Holdings Plc stock.

MeiraGTx Holdings Plc (NASDAQ: MGTX) is a clinical-stage leader in gene therapy innovation, developing transformative treatments for ocular, neurological, and salivary gland disorders. This dedicated news hub provides investors and industry professionals with timely updates on the company’s progress, regulatory milestones, and strategic initiatives.

Access authoritative information directly from corporate announcements and verified sources. Track developments across MeiraGTx’s pipeline including clinical trial results for inherited retinal diseases, Parkinson’s disease research updates, and advancements in radiation-induced xerostomia therapies. The repository also features financial disclosures, manufacturing expansions, and partnership announcements.

Key updates include progress on the company’s proprietary riboswitch platform, AAV vector manufacturing innovations, and regulatory interactions. All content is curated to support informed analysis of MeiraGTx’s position in the gene therapy landscape while maintaining strict compliance with financial reporting standards.

Bookmark this page for streamlined access to essential MGTX updates. Combine our news tracking with Stock Titan’s analysis tools to monitor the company’s progress in advancing genetic medicines from clinical development to potential commercialization.

Rhea-AI Summary

MeiraGTx Holdings (Nasdaq: MGTX) announced that CEO Alexandria Forbes, Ph.D., will speak at several key conferences in May 2021. The events include the BofA Securities 2021 Virtual Health Care Conference on May 12, the RBC Capital Markets Global Healthcare Conference on May 19, and Oppenheimer's Rare & Orphan Disease Summit on May 21. Live webcasts will be available on the Company’s Investors page. MeiraGTx focuses on gene therapies for inherited retinal diseases, neurodegenerative diseases, and severe xerostomia, with multiple programs in clinical development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
conferences
-
Rhea-AI Summary

MeiraGTx Holdings (Nasdaq: MGTX) will participate in a fireside chat at the Chardan Virtual Genetic Medicines Manufacturing Summit on April 26, 2021, at 1:45 p.m. ET. The discussion will feature CEO Alexandria Forbes and CDO Stuart Naylor.

A live webcast will be available on the company’s Investors page, and a replay will be accessible for 90 days post-event. MeiraGTx is focused on gene therapy solutions for inherited retinal diseases, neurodegenerative conditions, and xerostomia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.5%
Tags
conferences
-
Rhea-AI Summary

MeiraGTx Holdings announced significant progress in its clinical programs and operational results for 2020. Highlights include positive preliminary data from its Phase 1 AQUAx trial for xerostomia and the upcoming Phase 3 Lumeos trial for AAV-RPGR. The company strengthened its balance sheet with $209 million in cash and extended its cash runway into mid-2023. MeiraGTx also reported a net loss of $58 million for 2020, despite an increase in license revenue from collaborations. The new cGMP plasmid and DNA manufacturing facility adds to their capabilities for clinical development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.94%
Tags
none
Rhea-AI Summary

MeiraGTx Holdings (Nasdaq: MGTX) announced that CEO Alexandria Forbes will present at the Barclays Global Healthcare Conference on March 11, 2021, at 11:30 a.m. ET. A live webcast will be available on the Company’s investor website, with a replay accessible for 30 days post-presentation.

MeiraGTx is a clinical stage gene therapy company with six clinical programs addressing unmet medical needs in inherited retinal diseases, neurodegenerative diseases, and xerostomia. The company focuses on viral vector design and gene therapy manufacturing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
conferences
-
Rhea-AI Summary

MeiraGTx Holdings Plc (NASDAQ:MGTX) has announced that the FDA granted Fast Track designation to its AAV-CNGA3 gene therapy for achromatopsia (ACHM) caused by mutations in the CNGA3 gene. This designation facilitates expedited development and review of drugs addressing serious conditions. Currently, MeiraGTx is conducting a Phase 1/2 clinical trial for AAV-CNGA3. This is the third Fast Track designation for the company’s retinal disease products, emphasizing the high unmet medical need for effective therapies in this area.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
none
-
Rhea-AI Summary

MeiraGTx Holdings (Nasdaq: MGTX) will hold a webcast and conference call on December 17, 2020, at 8:00 a.m. ET to discuss the AAV-hAQP1 clinical program targeting radiation-induced xerostomia. They will share results from the first cohort of three patients in the Phase 1 AQUAx clinical trial, where one patient exhibited complete symptom resolution at the 12-month mark. The treatment showed good tolerance with no serious adverse effects. This update will feature insights from key presenters, including CEO Alexandria Forbes and trial investigator Dr. Michael Brennan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.23%
Tags
conferences
Rhea-AI Summary

MeiraGTx Holdings plc (Nasdaq: MGTX) announced that CEO Alexandria Forbes, Ph.D., will present at the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020, at 10:05 a.m. ET. The presentation will be available via a live webcast on the company's Investors page. MeiraGTx is a clinical-stage gene therapy company with six programs in development, focusing on inherited retinal diseases, neurodegenerative diseases, and severe forms of xerostomia. The company aims to address significant medical needs through innovative gene therapy solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.97%
Tags
conferences
-
Rhea-AI Summary

MeiraGTx Holdings plc (Nasdaq: MGTX) announced that Dr. Alexandria Forbes, CEO, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. The chat is pre-recorded and accessible on the Company's investor website, with a replay available for 90 days. MeiraGTx is a clinical stage gene therapy company focusing on inherited retinal diseases, neurodegenerative diseases, and xerostomia, with a strong pipeline and innovative gene regulation technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
conferences
-
Rhea-AI Summary

MeiraGTx Holdings plc (Nasdaq:MGTX) announced a public offering of 5,000,000 ordinary shares priced at $12.85 each, with expected gross proceeds of approximately $64.3 million. The underwriters also have a 30-day option to purchase an additional 750,000 shares. The offering is anticipated to close around November 23, 2020. The shares are offered under an effective registration statement previously filed with the SEC. The press release highlights potential risks and uncertainties related to the company's financial performance and market conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.03%
Tags
Rhea-AI Summary

MeiraGTx Holdings plc (NASDAQ:MGTX) announced a public offering of 5,000,000 ordinary shares, with a potential additional sale of 750,000 shares by underwriters. The offering is being managed by BofA Securities, Piper Sandler, Evercore ISI, Barclays, and Chardan. Proceeds will fund general corporate purposes, including working capital. This follows an effective shelf registration with the SEC from 2019. The final offering terms will be disclosed later. The company highlighted that the offering is subject to market conditions, and there are no guarantees of completion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.03%
Tags

FAQ

What is the current stock price of Meiragtx Holdings Plc (MGTX)?

The current stock price of Meiragtx Holdings Plc (MGTX) is $6.81 as of April 28, 2025.

What is the market cap of Meiragtx Holdings Plc (MGTX)?

The market cap of Meiragtx Holdings Plc (MGTX) is approximately 445.5M.
Meiragtx Holdings Plc

Nasdaq:MGTX

MGTX Rankings

MGTX Stock Data

445.53M
46.68M
39.24%
58.91%
2.53%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
NEW YORK